Karin you wrote: "Though it was hoped that it would reduce tumors, it was always considered to be primarily effective as a combination therapy." The patients in this trial were undergoing the combination therapy, so tumor reduction would be expected with efficacy. The focus of the trial was the primary outcome, the biomarker results.
In our truncated sample of 2, we apparently got positive biomarker data (though not tumor reduction). This is possible signal, so the company is aiming to get the K pill developed and re-try with a proper Phase 2A/B sample size and effective dosing. Hopefully the next trial will happen and show tumor reduction.
News 
Market Data 
Discover 
